52 results
Page 2 of 3
6-K
EX-99.1
yx0fxod
29 Sep 22
InflaRx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients
8:00am
6-K
EX-99.1
8lamw
8 Sep 22
InflaRx Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in The Lancet Respiratory Medicine
8:00am
6-K
EX-99.3
gqknl3b as8
5 Aug 22
Current report (foreign)
6:07am
6-K
EX-99.1
kmtmhf1fqe23t
26 Jul 22
InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients
8:35am
6-K
EX-99.3
6iv6 46c8
12 May 22
Current report (foreign)
8:30am
6-K
EX-99.1
qo0tsavwqgdt7bpu
7 Apr 22
Current report (foreign)
4:01pm
6-K
EX-99.1
2yb omgv57tr
31 Mar 22
InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients
4:51pm
6-K
EX-5.2
fm5ad1z9c9ri9j27ozh
1 Mar 21
Current report (foreign)
12:00am
6-K
EX-99.1
xsm0vsk
1 Mar 21
Current report (foreign)
12:00am
424B5
wsnipeyd14
26 Feb 21
Prospectus supplement for primary offering
5:10pm
424B5
sr60a90y84k8f
24 Feb 21
Prospectus supplement for primary offering
5:16pm
6-K
iiyitk 2309bu6ndxbml
24 Feb 21
Current report (foreign)
4:16pm
424B5
saoo1h haeqpzhq
20 Jul 20
Prospectus supplement for primary offering
9:21am
6-K
EX-99.1
utypn giya1t2jw
20 Jul 20
from 6-K
9:02am
F-3
EX-5.2
7y6ykf4s9nkipd
8 Jul 20
Shelf registration (foreign)
12:00am
F-3
l50lyxktn2
8 Jul 20
Shelf registration (foreign)
12:00am